[Form 4] Sana Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider acquisition recorded for Sana Biotechnology (SANA). A Form 4 filed for director Hans Edgar Bishop shows an acquisition on 10/06/2025 of 5,628 shares via fully vested restricted stock units (RSUs) issued at $0.00 as part of compensation. Following the transaction, the reporting person beneficially owns 5,834,583 shares in total. The filing was signed by an attorney-in-fact on 10/07/2025. The entry is coded as a non-derivative acquisition and the explanation confirms these were fully vested RSUs.

Positive

• Director increased stake by 5,628 shares via fully vested RSUs
• Total beneficial ownership remains substantial at 5,834,583 shares

Negative

• None.

Insights

Corporate Governance Analyst

Director acquired vested RSUs, modestly increasing direct holdings.

The filing documents a non-cash acquisition of 5,628 common shares through fully vested restricted stock units on 10/06/2025, recorded at an exercise/issue price of $0.00. This transaction reflects standard compensation vesting rather than an open-market purchase.

The main dependency is executive equity compensation schedules; the filing does not disclose new grants or accelerated vesting beyond the single RSU vesting event. Monitor future Form 4s for any market purchases or sales that would more actively signal insider conviction within the next 30–90 days.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bishop Hans Edgar

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 400

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/06/2025		A		5,628(1)	A	$0.00	5,834,583	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of fully vested restricted stock units.

Remarks:

	/s/ Bernard J. Cassidy, Attorney-in-Fact for Hans Edgar Bishop	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the SANA Form 4 filed for Hans Edgar Bishop report?

The Form 4 reports an acquisition on 10/06/2025 of 5,628 shares through fully vested restricted stock units, with total beneficial ownership of 5,834,583 shares.

Was the acquisition a market purchase or compensation-related?

The acquisition consisted of fully vested RSUs issued at $0.00, indicating it was compensation-related rather than an open-market trade.

Does the Form 4 indicate any derivative transactions for SANA?

No. The filing shows a non-derivative transaction only; Table II for derivative securities contains no reported transactions.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact on 10/07/2025 following the 10/06/2025 transaction date.

How significant is the reported change in holdings for SANA insiders?

The change was 5,628 shares from vested RSUs. The filing lists total beneficial ownership at 5,834,583 shares, which provides context for the director's overall stake.